Positive Press Coverage Likely to Impact Hologic (HOLX) Stock Price

News headlines about Hologic (NASDAQ:HOLX) have been trending positive recently, Alpha One Sentiment reports. The research group, a service of Accern, identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Hologic earned a media sentiment score of 0.30 on Alpha One’s scale. Alpha One also gave media headlines about the medical equipment provider an impact score of 77 out of 100, indicating that recent press coverage is likely to have an impact on the stock’s share price in the next several days.

These are some of the news stories that may have effected Alpha One’s scoring:

Shares of Hologic (NASDAQ:HOLX) traded down 0.14% on Friday, hitting $43.20. 1,497,260 shares of the company traded hands. The firm has a market capitalization of $12.07 billion, a P/E ratio of 36.92 and a beta of 1.10. Hologic has a 1-year low of $32.64 and a 1-year high of $43.30. The firm’s 50-day moving average is $42.33 and its 200 day moving average is $39.95.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 1st. The medical equipment provider reported $0.52 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.51 by $0.01. The business had revenue of $734.40 million for the quarter, compared to analyst estimates of $725.01 million. Hologic had a return on equity of 27.17% and a net margin of 11.57%. The company’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.46 earnings per share. On average, analysts anticipate that Hologic will post $1.98 earnings per share for the current fiscal year.

A number of equities analysts have recently commented on HOLX shares. Piper Jaffray Companies raised shares of Hologic from a “neutral” rating to an “overweight” rating and increased their price target for the company from $44.00 to $48.00 in a research report on Wednesday, January 4th. Evercore ISI cut shares of Hologic from a “buy” rating to a “hold” rating and set a $42.00 price target for the company. in a research report on Wednesday, January 4th. Zacks Investment Research raised shares of Hologic from a “hold” rating to a “buy” rating and set a $45.00 price target for the company in a research report on Friday, January 6th. Jefferies Group LLC reissued a “buy” rating and set a $46.00 price target on shares of Hologic in a research report on Sunday, January 8th. Finally, Deutsche Bank AG reissued a “buy” rating and set a $48.00 price target on shares of Hologic in a research report on Wednesday, January 18th. Four equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Hologic currently has an average rating of “Buy” and an average price target of $46.92.

COPYRIGHT VIOLATION WARNING: This story was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/04/21/favorable-press-coverage-likely-to-effect-hologic-holx-share-price-updated.html.

In other news, Director Elaine Ullian sold 9,104 shares of the company’s stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $42.40, for a total value of $386,009.60. Following the sale, the director now directly owns 23,810 shares in the company, valued at $1,009,544. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Lawrence M. Levy sold 10,757 shares of the company’s stock in a transaction on Wednesday, April 12th. The shares were sold at an average price of $42.45, for a total value of $456,634.65. Following the completion of the transaction, the director now owns 24,596 shares of the company’s stock, valued at $1,044,100.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 46,680 shares of company stock worth $1,945,862. 0.79% of the stock is owned by company insiders.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

5 Day Chart for NASDAQ:HOLX

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply